Shuttle Pharmaceuticals Holdings Inc (SHPH)

Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining RigsMay 14, 2026 4:05 PM
NewsfileInitial Mining Fleet Targeted for Deployment Within 60 Days of Receipt; To Mine DOGE and LTC and Accumulate Mined Coins as Long-Term Treasury AssetsGaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced the closing (the "Closing") of its previously announced merger with United Dogecoin Inc. ("United Dogecoin"), and the confirmation of a purchase order granting the Company the option to purchase up to 3,000 next-generation ElphaPex Scrypt mining rigs ("Mining Rigs") for use in the Company's Dogecoin (DOGE) and Litecoin (LTC) merge-mining operations. As previously reported on Shuttle's Current Report on Form-8-K dated May 7, 2026 (the "Closing 8-K"), filed with the U.S. Securities and Exchange Commission (the "SEC"), the Closing was completed on May 6, 2026. Effective at Closing, United Dogecoin became a wholly owned subsidiary of Shuttle. The combined company is now positioned to pursue a focused strategy of mining DOGE and LTC and accumulating mined coins on its balance sheet.Transaction Closing
In connection with the Closing, Shuttle:Issued 8,000 shares of Series B-1 Convertible Preferred Stock to United Dogecoin equity holders, which, subject to stockholder approval, are convertible into approximately 32,264,000 shares of Shuttle common stock;Reserved up to 118,038,551 pre-funded warrants for issuance to United Dogecoin equity holders, subject to the achievement of specified post-Closing operational milestones and receipt of Shuttle stockholder approval; andCompleted the previously announced $9.55 million private placement financing ("PIPE Financing").Additional information regarding the Closing and the related securities issuances are set forth in the Closing 8-K.Initial 3,000 Rig Purchase Order
Today, the Company has confirmed receipt of a purchase order granting them the option to purchase up to 3,000 next-generation ElphaPex mining rigs. The rigs utilize the Scrypt hashing algorithm and are capable of merge-mining Dogecoin and Litecoin simultaneously, allowing the Company to capture rewards from both networks from a single fleet.Once fully deployed, the fleet is expected to deliver up to approximately 43,200 GH/s of total hash rate. Subject to delivery and site readiness, the Company expects to begin bringing the rigs online within 60 days of equipment receipt.Management Commentary
"The confirmation of our initial rig purchase order marks the start of what we believe can become one of the most prominent publicly traded Dogecoin and Litecoin mining platforms in the market today," said Ryan Trasolini, Co-Chief Executive Officer of Shuttle and founder of United Dogecoin. "Our approach is disciplined and straightforward. Deploy efficient, new-generation ElphaPex mining rigs, mine DOGE and LTC at meaningful scale, and accumulate mined digital assets on our balance sheet with the goal of building consistent, long-term value for our stockholders."About United Dogecoin
United Dogecoin is a Dogecoin mining company built on three foundational advantages: scale, preferential access to best-in-class equipment, and an industry leading management team. Its mission is to establish and maintain category leadership in the Dogecoin sector through high-efficiency, low-cost mining operations and strategic coin accumulation, combining operational excellence, consistency and expert execution to build a robust reserve.About Shuttle Pharmaceuticals
Shuttle (NASDAQ: SHPH) owns a pharmaceutical software AI driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.Additional Information and Where To Find ItIn connection with the Closing, the PIPE Financing and related transactions, Shuttle intends to file with the SEC a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934 (the "Proxy Statement"), in preliminary and definitive form, and other required documents regarding the issuance of the securities underlying the securities issued in connection with the Closing and the PIPE Financing. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT, AS MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED BY SHUTTLE WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SHUTTLE, UNITED DOGECOIN, THE CLOSING, THE PIPE FINANCING, THE SECURITIES ISSUED IN THE CLOSING AND PIPE FINANCING AND THE RELATED RISKS AND RELATED MATTERS.The Definitive Proxy Statement will be mailed to stockholders of Shuttle. Investors will be able to obtain free copies of the Proxy Statement, as may be amended from time to time, and other relevant documents filed by Shuttle with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed with the SEC by Shuttle, including the Proxy Statement (when available), will be available free of charge from Shuttle's website at www.shuttlepharma.com under the "Investors" tab.Media and IR contactinfo@uniteddogecoin.cominfo@shuttlepharma.comCautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements regarding the post-Merger company and its operations, strategies and plans, capital expenditures, the purchase order for the Mining Rigs, the expected timing for the deployment of the Mining Rigs, the total hash rate the Mining Rigs are expected to generate and stockholder approval for the issuance of securities in connection with the exercise or conversion of securities issued in connection with the Closing and the PIPE Financing. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this press release. These include, among others, the risk that Shuttle's and United Dogecoin's businesses will not be integrated successfully, synergies and growth from the Closing may not be fully realized or may take longer to realize than expected; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the merger; failure to obtain or maintain required listing approvals or satisfy Nasdaq continued listing standards; risks relating to the volatile nature of the price of DOGE and other cryptocurrencies; risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; risks relating to the treatment of digital assets for U.S. and foreign tax purposes; risks related to the unknown returns that the post-merger company's DOGE treasury strategy will generate; risks related to unproven strategies; the risk that changes in Shuttle's capital structure and governance following the merger could have adverse effects on the market value of its securities; the ability of Shuttle and the post-merger company to retain customers and retain and hire key personnel and on Shuttle's and the post-merger company's operating results and business generally; the risk that Shuttle may be unable to reduce expenses or access financing or liquidity; the impact of any related economic downturn; the risk of changes in governmental regulations or enforcement practices; and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond Shuttle's and United Dogecoin's control, including those detailed in Shuttle's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and such other documents of Shuttle filed, or to be filed, with the SEC that are or will be available on Shuttle's website at www.shuttlepharma.com and on the website of the SEC at www.sec.gov. All forward-looking statements are based on assumptions that Shuttle and United Dogecoin believe to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and neither Shuttle nor United Dogecoin undertakes any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.Participants in the Solicitation
United Dogecoin, Shuttle, and their respective directors, executive officers, management and employees, under SEC rules, may be deemed to be participants in a solicitation of proxies of Shuttle' stockholders. Investors and stockholders may obtain more detailed information regarding the names, affiliations, and interests of Shuttle' directors and executive officers in its filings with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Shuttle stockholders will be set forth in the Proxy Statement. Such interests may in some cases be different from those of United Dogecoin's or Shuttle' equity holders generally.No Offer or Solicitation
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described in this press release in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus filed with the SEC meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an applicable exemption.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297554 Original: Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs

So when do we get the news on the closing of the pipe and machine purchase?

SHPH, to Become the World's Largest Public Dogecoin Miner

The combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percentage of the global hashrate
2026-04-30 16:06 ET - News Release


Gaithersburg, Maryland--(Newsfile Corp. - April 30, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. United Dogecoin will be merged into a wholly owned subsidiary of Shuttle. The merger is supported by a $11 million concurrent Private Investment in Public Equity ("PIPE") financing expected to close on May 4, 2026.

SHPH, Amazing news: United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation

The combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percentage of the global hashrate
2026-05-01 08:42 ET - News Release


Gaithersburg, Maryland--(Newsfile Corp. - May 1, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. United Dogecoin will be merged into a wholly owned subsidiary of Shuttle. The merger is supported by a $11 million concurrent Private Investment in Public Equity ("PIPE") financing expected to close on May 4, 2026.

United Dogecoin's competitive advantages begin with its size. Upon closing of the PIPE, United Dogecoin intends to secure a purchase order of up to 3,000 newest generation ElphaPex Mining Rigs. Within 60 days, the mining rigs are expected to be online, delivering a hash rate of up to 43,200 GH/s, approximately 1.5% of the world's Dogecoin mining capacity at this time.

United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining OperationMay 1, 2026 8:41 AM
NewsfileThe combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percentage of the global hashrateGaithersburg, Maryland--(Newsfile Corp. - May 1, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. United Dogecoin will be merged into a wholly owned subsidiary of Shuttle. The merger is supported by a $11 million concurrent Private Investment in Public Equity ("PIPE") financing expected to close on May 4, 2026. United Dogecoin's competitive advantages begin with its size. Upon closing of the PIPE, United Dogecoin intends to secure a purchase order of up to 3,000 newest generation ElphaPex Mining Rigs. Within 60 days, the mining rigs are expected to be online, delivering a hash rate of up to 43,200 GH/s, approximately 1.5% of the world's Dogecoin mining capacity at this time. Furthermore, United Dogecoin's existing relationship with ElphaPex, a leader in Dogecoin mining hardware, is expected to give the Company preferential access to ElphaPex's high-efficiency mining rigs at strategic pricing, which should reduce the time needed to scale operations as market opportunities arise. Through its existing relationships, United Dogecoin expects to generate DOGE at discount to purchasing on the open market even at current DOGE price range. It is expected to have access to providers of low-cost, behind-the-meter, renewable energy. United Dogecoin believes that its expected low-cost structure is the foundation of scalable, long-term growth.The United Dogecoin team has a track record of success operating and scaling public cryptocurrency mining companies. Its CEO, Ryan Trasolini, has over a decade of experience in building high growth ventures. He was one of the founding shareholders of US Bitcoin Corp which did a merger of equals with Hut 8, forming a $8B infrastructure platform. Trasolini subsequently co-founded American Data Centers, which partnered with Hut 8 to create American Bitcoin. "Through our size, relationships, expertise and timing, we believe that we are uniquely positioned to be a global leader in Dogecoin mining," said Ryan Trasolini, CEO of United Dogecoin and to be the co-CEO of the combined company. "The completion of this transaction will give investors exposure to Dogecoin via our dual-pronged strategy of mining Dogecoin with highly efficient, cost-effective rigs and holding mined Dogecoin on our balance sheet to build long-term asset value. This strategy has been successful in Bitcoin mining, and we are ready to apply it to Dogecoin mining with a view to deliver long-term shareholder value.""United Dogecoin's strategy mirrors that of Hut 8's back in 2017," said Andrew Kiguel, CEO of Realbotix, co-founder of Hut 8 and United Dogecoin board member. "We believe that while the opportunity for incredible upside in new Bitcoin miners has passed, Dogecoin mining is in its infancy, and United Dogecoin is well positioned to be a leader in the space."Company LeadershipThe Company's Board of Directors expects to appoint Mr. Trasolini as Co-Chief Executive Officer with Christopher Cooper. Yuying Liang will continue in her role as Chief Financial Officer, providing continuity in financial leadership. It is expected that Mr. Trasolini will enter into a customary employment agreement with Shuttle.Merger HighlightsUnder the terms of the merger agreement, signed April 30, 2026, Shuttle will issue an aggregate of 8,000 of a newly designated Series B-1 Convertible Preferred Stock to United Dogecoin's equity holders in exchange for 100% of the outstanding shares of United Dogecoin. Upon subsequent receipt of Shuttle stockholder approval, the shares of Series B-1 Convertible Preferred Stock will be automatically convertible, at a conversion price of $1.24 (subject to adjustment), into an aggregate of approximately 32,258,064 shares of Shuttle's common stock, par value $0.00001 per share (the "Company Common Stock"), subject to customary beneficial ownership limitations. Following the consummation of the merger, United Dogecoin will merge with and into, and become, a wholly-owned subsidiary of Shuttle, and will operate alongside Shuttle's existing business.In addition, United Dogecoin equityholders will receive up to 118,038,551 pre-funded warrants ("Pre-Funded Warrants") exercisable for a like number of shares of Company Common Stock upon the new wholly-owned subsidiary meeting certain operational milestones post-closing (the "Milestones"). Such Pre-Funded Warrants will be issued only in the event Shuttle obtains stockholder approval.PIPE HighlightsIn connection with the Merger, Shuttle entered into a securities purchase agreement with certain accredited investors in a concurrent private placement offering of 2,200 shares of newly designated Series B-2 Convertible Preferred Stock and common warrants ("Common Warrants") to purchase 100% of the number of shares of Company Common Stock underlying the Series B-2 Convertible Preferred Stock (10,679,612 shares) (the "Offering"). Upon subsequent receipt of Shuttle stockholder approval, the shares of Series B-2 Convertible Preferred Stock will be automatically convertible, at a conversion price of $1.03 (subject to adjustment), into an aggregate of approximately 9,708,738 shares of Company Common Stock, subject to customary beneficial ownership limitations. The Common Warrants have an exercise price of $1.03 and a 3-year term. The Series B-2 Convertible Preferred Stock and the Common Warrants issued in the Offering will not be exercisable or convertible until stockholder approval is obtained.In addition, investors in the PIPE will receive up to 34,932,064 pre-funded warrants to purchase a like number of shares of Company Common Stock upon the post-merger company meeting the Milestones, which securities will be issued only in the event Shuttle obtains stockholder approval.AdvisorsE.F. Hutton & Co. ("E.F. Hutton") is proud to have served as the exclusive M&A advisor to Shuttle in connection with the merger, and as the exclusive placement agent for the concurrent PIPE financing. Sullivan & Worcester LLP acted as legal advisor to Shuttle. Ruskin Moscou Faltischek PC acted as legal advisor to United Dogecoin. McDermott Will & Schulte acted as legal advisor to E.F. Hutton.About United DogecoinUnited Dogecoin is a Dogecoin mining company with competitive advantages in its size, access to equipment, and industry leading team. Its mission is to be the leader in the Dogecoin sector through high-efficiency, low-cost mining operations and strategic coin accumulation, building a robust reserve that strengthens its long-term position and sets it apart through innovation, consistency and expert execution.About Shuttle PharmaceuticalsShuttle (NASDAQ: SHPH) owns a pharmaceutical software AI driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.Additional Information and Where To Find ItIn connection with the merger, the PIPE and related transactions, Shuttle intends to file with the U.S. Securities and Exchange Commission (the "SEC") a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934 (the "Proxy Statement"), in preliminary and definitive form, and other required documents regarding the issuance of the securities underlying the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT, AS MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED BY SHUTTLE WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SHUTTLE, UNITED DOGECOIN, THE MERGER, THE PIPE, THE SECURITIES AND THE RELATED RISKS AND RELATED MATTERS.The Definitive Proxy Statement will be mailed to stockholders of Shuttle. Investors will be able to obtain free copies of the Proxy Statement, as may be amended from time to time, and other relevant documents filed by Shuttle with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed with the SEC by Shuttle, including the Proxy Statement (when available), will be available free of charge from Shuttle's website at www.shuttlepharma.com under the "Investors" tab.Media and IR contactinfo@uniteddogecoin.comCautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the completion of the offering. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.These forward-looking statements include, but are not limited to, statements regarding the merger (including any related post-closing actions), the post-merger company and its operations, strategies and plans, integration of businesses, governance changes, capital expenditures, cash flows and anticipated uses, synergies, opportunities and anticipated future performance, including the management team and board of directors of the post-merger company, expected use of proceeds from the PIPE offering and other financing activities, any future acquisitions and the maintenance of reserves and related arrangements. Information adjusted for the impact of the merger should not be considered a forecast of future results.There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this report. These include, among others, the risk that the proposed transactions described herein may not be completed in a timely manner or at all; the risk that Shuttle's and United Dogecoin's businesses will not be integrated successfully, synergies and growth from the merger may not be fully realized or may take longer to realize than expected; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the merger; failure to obtain or maintain required listing approvals or satisfy Nasdaq continued listing standards; inability to consummate planned financings on acceptable terms or within expected timeframes; risks relating to the volatile nature of the price of DOGE and other cryptocurrencies; risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; risks relating to the treatment of digital assets for U.S. and foreign tax purposes; risks related to the unknown returns that the post-merger company's DOGE treasury strategy will generate; risks related to unproven strategies; the risk that changes in Shuttle's capital structure and governance following the merger could have adverse effects on the market value of its securities; the ability of Shuttle and the post-merger company to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on Shuttle's and the post-merger company's operating results and business generally; the risk the merger could distract management from ongoing business operations or cause Shuttle or the post-merger company to incur substantial costs; the risk that Shuttle may be unable to reduce expenses or access financing or liquidity; the impact of any related economic downturn; the risk of changes in governmental regulations or enforcement practices; and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond Shuttle's and United Dogecoin's control, including those detailed in Shuttle's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and such other documents of Shuttle filed, or to be filed, with the SEC that are or will be available on Shuttle's website at www.shuttlepharma.com and on the website of the SEC at www.sec.gov. All forward-looking statements are based on assumptions that Shuttle and United Dogecoin believe to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and neither Shuttle nor United Dogecoin undertakes any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.Participants in the SolicitationUnited Dogecoin, Shuttle, and their respective directors, executive officers, management and employees, under SEC rules, may be deemed to be participants in a solicitation of proxies of Shuttle' stockholders. Investors and stockholders may obtain more detailed information regarding the names, affiliations, and interests of Shuttle' directors and executive officers in its filings with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Shuttle stockholders will be set forth in the Proxy Statement. Such interests may in some cases be different from those of United Dogecoin's or Shuttle' equity holders generally.No Offer or SolicitationThis communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described in this press release in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus filed with the SEC meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an applicable exemption.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295426
Original: United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation

SHPH news .. Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner https://investorshub.advfn.com/stock-market/NASDAQ/shuttle-pharmaceuticals-SHPH/stock-news/98411083/shuttle-merges-with-united-dogecoin-to-become-the

RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 27, 2026 8:00 AM
NewsfileGaithersburg, Maryland--(Newsfile Corp. - March 27, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development.The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic candidates. By integrating enhanced predictive and generative capabilities into a unified platform, Shuttle Pharma is accelerating the transition from fragmented data analysis toward a scalable, end-to-end solution for therapeutic development.This update marks a critical evolution for AI-driven drug discovery: from standalone model outputs to a more sophisticated reasoning system. The platform can now identify and prioritize relationships between genes and disease pathways and predict compound interactions with specific biological targets. Combined with existing molecular prediction tools, molecule.ai delivers a more connected and efficient framework for evaluating therapeutic opportunities—driving faster, higher-confidence decision-making earlier in the discovery lifecycle.In addition, the Company unveiled a preview of its next-generation autonomous AI agent system, built on top of frontier AI models. This system is designed to move beyond traditional single-step predictions by enabling multi-step reasoning and multi-agent orchestration across complex scientific workflows. The agents will be capable of ingesting multimodal data, leveraging integrated tools, and executing discrete research tasks—dramatically reducing manual effort and increasing throughput for research teams."This release represents a meaningful step toward fully autonomous therapeutic discovery," said Chris Cooper, Chief Executive Officer of Shuttle Pharma. "We are not just improving model performance—we are redefining how drug development workflows are executed. By integrating reasoning, prediction, and automation into a single platform, molecule.ai has the potential to materially reduce timelines, lower costs, and increase the probability of success across the development pipeline. We believe this positions Shuttle Pharma to play a leading role in the next generation of AI-powered biopharma innovation."As Shuttle Pharma continues to expand molecule.ai's capabilities, the Company remains focused on building a scalable platform that can unlock new therapeutic opportunities, improve development efficiency, and create long-term value for shareholders.About Shuttle PharmaShuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) owns a pharmaceutical software artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development. Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the development and future capabilities of the Molecule.ai platform. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our ability to realize the anticipated benefits from the Molecule.ai platform, risks related to the acquisition and retention of future customers and our ability to generate revenue, our ability to fund our future operations, risks regarding our intellectual property, risks regarding our ability to maintain the listing of our common stock on Nasdaq, as well as other factors discussed in Shuttle Pharma's SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.Shuttle Pharmaceuticals
Chris Cooper
Chief Executive Officer
info@shuttlepharma.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/290201
Original: RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 26, 2026 4:05 PM
NewsfileGaithersburg, Maryland--(Newsfile Corp. - March 26, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development.The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic candidates. By integrating enhanced predictive and generative capabilities into a unified platform, Shuttle Pharma is accelerating the transition from fragmented data analysis toward a scalable, end-to-end solution for therapeutic development.This update marks a critical evolution for AI-driven drug discovery: from standalone model outputs to a more sophisticated reasoning system. The platform can now identify and prioritize relationships between genes and disease pathways and predict compound interactions with specific biological targets. Combined with existing molecular prediction tools, molecule.ai delivers a more connected and efficient framework for evaluating therapeutic opportunities-driving faster, higher-confidence decision-making earlier in the discovery lifecycle.In addition, the Company unveiled a preview of its next-generation autonomous AI agent system, built on top of frontier AI models. This system is designed to move beyond traditional single-step predictions by enabling multi-step reasoning and multi-agent orchestration across complex scientific workflows. The agents will be capable of ingesting multimodal data, leveraging integrated tools, and executing discrete research tasks-dramatically reducing manual effort and increasing throughput for research teams."This release represents a meaningful step toward fully autonomous therapeutic discovery," said Chris Cooper, Chief Executive Officer of Shuttle Pharma. "We are not just improving model performance-we are redefining how drug development workflows are executed. By integrating reasoning, prediction, and automation into a single platform, molecule.ai has the potential to materially reduce timelines, lower costs, and increase the probability of success across the development pipeline. We believe this positions Shuttle Pharma to play a leading role in the next generation of AI-powered biopharma innovation."As Shuttle Pharma continues to expand molecule.ai's capabilities, the Company remains focused on building a scalable platform that can unlock new therapeutic opportunities, improve development efficiency, and create long-term value for shareholders.About Shuttle PharmaShuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) owns a pharmaceutical software artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development. Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the development and future capabilities of the Molecule.ai platform. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our ability to realize the anticipated benefits from the Molecule.ai platform, risks related to the acquisition and retention of future customers and our ability to generate revenue, our ability to fund our future operations, risks regarding our intellectual property, risks regarding our ability to maintain the listing of our common stock on Nasdaq, as well as other factors discussed in Shuttle Pharma's SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.Shuttle Pharmaceuticals
Chris Cooper
Chief Executive Officer
info@shuttlepharma.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/289953
Original: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Shuttle Pharmaceuticals Announces $3.5 Million Public OfferingMarch 6, 2026 8:00 AM
NewsfileGaithersburg, Maryland--(Newsfile Corp. - March 6, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development, today announced that it has entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common stock, in a public offering, for aggregate gross proceeds of approximately $3,500,000, before deducting placement agent fees and other offering expenses. The offering is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions. E.F. Hutton & Co. is acting as the exclusive placement agent for the offering. The Company intends to use up to $1.5 million of the net proceeds from this offering for future marketing efforts and the remainder for working capital and general corporate purposes.The securities described above are being offered and sold by the Company in a public offering pursuant to a registration statement on Form S-1 (File No. 333-293363) that was originally filed with the Securities and Exchange Commission (the "SEC") on February 11, 2026, and became effective on February 17, 2026. The offering of the securities is being made only by means of a prospectus that forms a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. A final prospectus relating to, and describing the terms of, the public offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus relating to the public offering, when available, may also be obtained by contacting E.F. Hutton & Co., at 745 Fifth Avenue, 34th Floor & PH, New York, NY 10151, by telephone at v, or by email at info@efhutton.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About Shuttle PharmaceuticalsShuttle Pharma (NASDAQ: SHPH) owns a pharmaceutical software AI driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the completion of the offering. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks related to our ability to satisfy the closing conditions related to the offering, general economic and market risks, and factors discussed in the "Risk Factors" section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286465
Original: Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Bought 2.29,been watching all day and it’s starting to move freely ,zero borrow/420% fee,1.6m,outstanding,1.4m float,chart is great,big loading for over a week,5k-20k blocks today,could be news soon

shph..................................................................p/m

SHPH.......................................................https://stockcharts.com/sc3/ui/?s=SHPH&p=w&b=5&g=0&id=p86431144783

SHPH..............................................https://stockcharts.com/sc3/ui/?s=SHPH&p=w&b=5&g=0&id=p86431144783

SHPH..............................https://stockcharts.com/sc3/ui/?s=SHPH&p=w&b=5&g=0&id=p86431144783

SHPH..........................................https://stockcharts.com/sc3/ui/?s=SHPH&p=W&b=5&g=0&id=p86431144783

Cure for all $1.92

SHPH...........................................https://stockcharts.com/sc3/ui/?s=SHPH&p=W&b=5&g=0&id=p86431144783

2.20

2.01 cure for cancer 

Tradezero short $1.46

Coming down as $2.23 at $2.10

$2.08 the offering killing stock price so far

$3.46 and $4 offering see what happens 

SHPH..................................................................p/m

$4.06 Lots of dilution happening. Little pump followed by big dump shareholders must pay the Piper . Company still broke 

shph..............................................https://stockcharts.com/h-sc/ui?s=SHPH&p=W&b=5&g=0&id=p86431144783

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market
GAITHERSBURG, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company, today announced the execution of a non-binding letter of Intent with Molecule.ai.

Molecule.ai, a pioneering artificial intelligence company founded by AI scientist and researcher Dr. ZT Zhang, PhD, today announced the execution of a letter of Intent to acquire Molecule.ai and its state-of-the-art platform designed to transform the way pharmaceutical and biotech companies discover and develop new therapeutics.

By leveraging advanced machine learning models, including large language models (LLMs), Molecule.ai delivers industry-leading accuracy and efficiency in evaluating novel molecules. The platform enables researchers to shorten development timelines, reduce costs, and increase the likelihood of identifying successful therapeutic candidates.

“Our vision is to empower scientists with the most advanced AI-driven tools to push the boundaries of drug discovery,” said Dr. ZT Zhang, Founder and CEO of Molecule.ai. “With Molecule.ai, we are not just accelerating the process — we are fundamentally changing what’s possible in the search for new therapies.”

The Molecule.ai platform introduces several groundbreaking capabilities:

Molecule Property Prediction and Reasoning – Rapid and large-scale evaluation of chemical and biological properties across massive compound libraries, including novel and previously uncharacterized molecules.
Drug-Target Interaction Modeling – A powerful new feature that identifies and optimizes molecule-target interactions, paving the way for more precise therapeutic design.
Agentic AI Mode – An autonomous framework that enables AI agents to perform multi-step drug discovery workflows, from compound screening through optimization, significantly reducing manual effort.
With these innovations, Molecule.ai positions itself as a trusted partner for pharmaceutical and biotechnology organizations aiming to accelerate discovery and bring life-saving treatments to market faster.

Terms of the non-binding letter of Intent are as follows:

Shuttle will acquire all of the rights, title and interests Molecule.ai has free and clear of all liens.

Shuttle will assume all liabilities in respect of Molecule.ai and at Closing (as defined below), Molecule.ai shall have no further obligations or liabilities thereunder.

Molecule.ai will extend the current AI model and platform to support Drug-Target Interaction.

Molecule.ai will add first version of Agentic AI mode that enables an automatic workflow for drug discovery.

Molecule.ai will serve as lead liaison and headhunter, leveraging its relationships in the artificial intelligence community to recruit additional employees and strengthen the team.

Consideration:

As consideration for the purchase and the Transaction, and Shuttle’s assumption of its obligations and liabilities, Shuttle shall pay to Molecule.ai, at closing, a purchase price of $10 million payable, subject to the completion of the milestones, in a combination of cash and common shares of Shuttle. Consideration will be paid to Molecule.ai based upon certain milestones to be determined by both parties.

About Molecule.ai

Molecule.ai is an advanced artificial intelligence company focused on revolutionizing drug discovery and development. Founded by Dr. ZT Zhang, PhD, the company applies cutting-edge machine learning models and large language

SHPH........................................................................................a/h

SHPH..........................................................................https://stockcharts.com/h-sc/ui?s=SHPH&p=W&b=5&g=0&id=p86431144783

please dont run just yet.. i need a lot more

All Top level staff deferring 70% of salary at later time Bullish

What gives this ticker potential

Agreed !!!

Need interests and volume to make big move like devs !

Great time to buy up here. Good things in the making for future gains ! GLTA SHPH $$$

Let's break .30

SHPH......................................https://stockcharts.com/h-sc/ui?s=SHPH&p=W&b=5&g=0&id=p86431144783

Yes indeed !!!

The next RGC in the making. Just 9 employees with a soon to be $100 million profit to start. No brainer.

Yes Frustrating for sure , but hopefully it will make some gains soon and hold!

I read news and pipeline and filing
...not bad but some reason pps can't spike like devs ! I notice it up .30 premarket and after-hours yesterday but can't hold gain!

I believe so. I'm in and just a waiting game now. I don't think it will go much lower hopefully only up from here!

Is this time get in??? 52 week low.....

Hopefully a Great week ahead! Let's go Yes! SHPH $$$

$SHPH: Back in it again here at $0.24


Added 100k shares


LFGGGGGGGgggggggggggggggg


GO $SHPH

Wown go red

Glad they got FDA approval. Market value is now well over $10. So many ignorant peeps that let us buy very very low LOL.

SHPH......................................................................https://stockcharts.com/h-sc/ui?s=SHPH&p=W&b=5&g=0&id=p86431144783

Watching for the ema/vwap crossover with increasing volume. Could get interesting.

Delayed reaction??????? Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatment sites reporting that the drug has been well tolerated and toxicity no greater than 2 on a scale of 1-5. Further, 84% of the enrolled patients have completed all seven cycles. Shuttle has begun analyzing pharmacokinetic/pharmacodynamic samples to compare the relationship between dose and response in terms of the extent and duration of Ropidoxuridine’s action. Our objective is to finalize enrollment later this year with follow up and data read out in 2026.

“We are incredibly encouraged by the expedited progress of our Phase 2 trial and the dedication of our team, clinical partners, and patients who are making this milestone possible,” commented Shuttle Pharma's Chairman and Chief Scientific Officer, Anatoly Dritschilo, M.D. “If approved, we believe that Ropidoxuridine has the potential to redefine the standard approach for how to care for patients with glioblastoma.”

Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle Pharma previously received Orphan Drug Designation from the FDA, providing Shuttle Pharma with potential marketing exclusivity upon obtaining FDA approval for treatment of this disease.

The Phase 2 clinical trial design initially randomizes 40 patients into two different dose levels of drug, with 20 patients receiving 1,200 mg/day and 20 patients receiving 960 mg/day, to determine an optimal dose for use in glioblastoma patients in combination with RT. After the optimal dose is identified, 14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point demonstrating increased survival as compared to historical controls.

The Phase 2 clinical trial is conducted at Georgetown University Medical Center, Allegheny Health Network (AHN) Cancer Institute, UNC Medical Center, the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, and Miami Cancer Institute, part of Baptist Health South Florida.

“This clinical trial is critical to the broader radiation therapy industry as we look to leverage radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to continued trial execution as we aim to improve the lives of millions of patients impacted by cancer and to bring hope to patients and families around the world,” Dr. Dritschilo concluded.

An estimated 800,000 patients in the US are treated with radiation therapy for their cancers yearly. According to the American Cancer Society and the American Society of Radiation Oncologists, about 50% are treated for curative purposes and the balance for palliative therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes, with this number expected to grow by more than 22% over the next five years.

More information about the Phase 2 study (NCT06359379) can be found at www.clinicaltrials.gov.

About Shuttle Pharmaceuticals

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.